Skip to main content
. 2022 May 20;13:858207. doi: 10.3389/fphar.2022.858207

FIGURE 2.

FIGURE 2

The cost-effectiveness acceptability curves for the toripalimab plus gemcitabine and cisplatin, camrelizumab plus gemcitabine and cisplatin. Abbreviation: GP, gemcitabine plus cisplatin.